Stock listing

NASDAQ:VRCA Verrica Pharmaceuticals Inc. Stock

Home listing (NASDAQ) of Verrica Pharmaceuticals Inc.

Follow Verrica Pharmaceuticals Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:VRCA

$3.19 USD +0.10 (+3.2%)

Close on Nov 6, 2026

Past year -10.9% · daily closes, Nov 6, 2025 – Nov 6, 2026, adjusted for splits
Day range
$3.10 – $3.38 USDNov 6, 2026
Volume
190,650 sharesNov 6, 2026
Market cap
$54.80M USDAt the close on Nov 6, 2026 · price × 17.18M shares outstanding
52-week range
$3.08 – $9.82 USDLowest and highest trades, Nov 7, 2025 – Nov 6, 2026
Traded on an average day
$335,027 USDMedian day 50,650 shares · last 3 months, Aug 6, 2026 – Nov 6, 2026
Verrica Pharmaceuticals Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:VRCA · Home$3.19 USD+0.10 (+3.2%)190,650$3.10$3.38$3.10$3.09Close on Nov 6, 2026

Daily closes

Last 3 months, Aug 6, 2026 – Nov 6, 2026 · NASDAQ:VRCA · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$3.19+0.10+3.2%$3.10$3.38$3.10190,650
$3.09-0.365-10.6%$3.44$3.55$3.08121,376
$3.455+0.165+5.0%$3.31$3.50$3.3130,629
$3.29+0.08+2.5%$3.35$3.42$3.2644,948
$3.21-0.14-4.2%$3.40$3.62$3.2055,797
$3.35-0.07-2.0%$3.42$3.47$3.2531,486
$3.42-0.06-1.7%$3.501$3.60$3.3927,078
$3.48+0.01+0.3%$3.45$3.565$3.3922,176
$3.47+0.05+1.5%$3.52$3.52$3.33527,984
$3.42-0.11-3.1%$3.55$3.68$3.3921,890
$3.53-0.30-7.8%$3.76$3.76$3.4021,000
$3.83+0.20+5.5%$3.50$4.17$3.50109,900
$3.63+0.16+4.6%$3.46$3.64$3.44160,400
$3.47+0.03+0.9%$3.44$3.56$3.3077,200
$3.44-0.155-4.3%$3.61$3.645$3.4279,800
$3.595-0.185-4.9%$3.85$3.95$3.48116,500
$3.78-0.05-1.3%$3.92$3.95$3.74664,300
$3.83+0.25+7.0%$3.54$3.92$3.5054,000
$3.58-0.43-10.7%$3.99$4.38$3.5182,800
$4.01-0.10-2.4%$4.20$4.20$4.0048,100
$4.11-0.07-1.7%$4.37$4.37$4.0646,600
$4.18+0.04+1.0%$4.14$4.29$4.0537,200
$4.14-0.07-1.7%$4.15$4.33$4.0647,600
$4.21-0.10-2.3%$4.36$4.41$4.1740,600
$4.31-0.07-1.6%$4.34$4.539$4.2534,300
$4.38-0.135-3.0%$4.56$4.843$4.3744,100
$4.515-0.28-5.8%$4.85$4.85$4.51554,500
$4.795+0.335+7.5%$4.51$5.04$4.5151,000
$4.46-0.14-3.0%$4.67$4.67$4.4533,700
$4.60+0.23+5.3%$4.33$4.63$4.3233,000
$4.37+0.01+0.2%$4.39$4.50$4.3672,800
$4.36-0.26-5.6%$4.62$4.642$4.35540,900
$4.62-0.10-2.1%$4.67$4.78$4.5541,300
$4.72+0.23+5.1%$4.50$4.90$4.5065,100
$4.49+0.04+0.9%$4.55$4.635$4.4029,600
$4.45-0.20-4.3%$4.61$4.74$4.45113,500
$4.65+0.12+2.6%$4.70$4.79$4.5741,300
$4.53-0.05-1.1%$4.66$4.695$4.5348,300
$4.58-0.20-4.2%$4.75$4.77$4.51446,400
$4.78-0.13-2.6%$4.91$5.06$4.7043,100
$4.91-0.04-0.8%$4.99$5.03$4.8041,900
$4.95-0.11-2.2%$5.06$5.25$4.8656,800
$5.06-0.20-3.8%$5.25$5.40$5.0547,800
$5.26-0.04-0.8%$5.30$5.414$5.04112,200
$5.30-0.06-1.1%$5.28$5.525$5.2512,200
$5.36-0.03-0.6%$5.48$5.63$5.2755,400
$5.39+0.15+2.9%$5.32$5.56$5.28431,100
$5.24-0.22-4.0%$5.36$5.56$5.2243,500
$5.46-0.23-4.0%$5.70$5.831$5.295106,400
$5.69+0.62+12.2%$5.12$5.86$5.00350,800
$5.07+0.16+3.3%$5.01$5.65$4.90533,600
$4.91-0.03-0.6%$4.86$5.055$4.8427,700
$4.94+0.07+1.4%$4.90$4.99$4.7554,900
$4.87+0.05+1.0%$4.81$4.95$4.6167,900
$4.82-0.04-0.8%$4.90$4.99$4.6478,800
$4.86-0.13-2.6%$4.99$5.181$4.83138,100
$4.99+0.31+6.6%$5.22$5.22$4.77169,800
$4.68-0.21-4.3%$4.90$5.00$4.6850,300
$4.89-0.08-1.6%$5.00$5.15$4.765179,700
$4.97+0.11+2.3%$4.89$5.098$4.7859,600
$4.86-0.23-4.5%$5.11$5.351$4.7756,300
$5.09-0.13-2.5%$5.19$5.25$5.0526,900
$5.22+0.10+2.0%$5.21$5.85$5.1282,200
$5.12+0.04+0.8%$5.18$5.34$5.0622,300
$5.08-0.28-5.2%$5.31$5.50$4.70126,300
$5.36-0.15-2.7%$5.58$5.87$5.2685,200
Ticker
NASDAQ:VRCA
Asset type
Stock
Sector
Health care
Industry
Pharmaceuticals
Exchange
NASDAQ
Currency
USD

What changed lately

Calls

Replays

  • Verrica Pharmaceuticals (NASDAQ:VRCA) Q2 2026 Earnings Call

    Thu, Aug 06, 2026 · 4:30 PM ET

    Watch Transcript

  • Verrica Pharmaceuticals (NASDAQ:VRCA) Q1 2026 Earnings Call

    Tue, May 12, 2026 · 4:30 PM ET

    Watch Transcript

  • Verrica Pharmaceuticals (NASDAQ:VRCA) Q4 2025 Earnings Call

    Wed, Mar 11, 2026 · 8:15 AM ET

    Watch Transcript

Latest news

Verrica Pharmaceuticals to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 12, 2026

Nov 5, 2026

Closed $3.09 (-10.6%) on Nov 5, 2026

Verrica Pharmaceuticals Announces Achievement of Milestones Unlocking Access to the Full $27.5 Million of Non-Dilutive Growth Capital Under Credit Facility

Oct 22, 2026

Closed $3.83 (+5.5%) on Oct 22, 2026

Verrica Pharmaceuticals to Present New YCANTH® Data Analysis at Two Upcoming Dermatology Conferences

Sep 30, 2026

Closed $4.80 (+7.5%) on Sep 30, 2026

Verrica Pharmaceuticals to Present YCANTH® and VP-315 Data at Two Upcoming Dermatology Conferences

Sep 10, 2026

Closed $4.95 (-2.2%) on Sep 10, 2026

Verrica Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Sep 8, 2026

Closed $5.26 (-0.8%) on Sep 8, 2026

Verrica Pharmaceuticals Announces Completion of Enrollment in First Pivotal Phase 3 Trial (COVE-2) Evaluating YCANTH® for the Treatment of Common Warts, with Topline Data Expected Q1 2027

Aug 27, 2026

Closed $5.07 (+3.3%) on Aug 27, 2026

Verrica Pharmaceuticals Reports Second Quarter 2026 Financial Results

Aug 6, 2026

Closed $5.08 (-5.2%) on Aug 7, 2026

Verrica Pharmaceuticals Closes Credit Facility For Up To $27.5 Million in Non-Dilutive Growth Capital

Aug 6, 2026

Closed $5.08 (-5.2%) on Aug 7, 2026

Verrica Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026

Jul 30, 2026

Closed $5.26 (+1.5%) on Jul 30, 2026

Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel

Jul 21, 2026

Closed $5.44 (-0.9%) on Jul 21, 2026

All Verrica Pharmaceuticals Inc. news

Financings

  • Private placement of common stock and pre-funded warrants with accompanying Series C warrants

    Nov 24, 2025

    Announced: about US$50M · US$4.2413 a share · Warrants at US$6.315 for 60 months · TD Cowen

    Dealers: TD Cowen (lead)

    Buyers: Caligan Partners LP (anchor investor; entitled to designate a new member to the Board); PBM Capital (anchor investor)

    Use of proceeds: $35.0 million to fully repay the OrbiMed credit agreement; the remainder for working capital and general corporate purposes

    Announced Nov 24, 2025

  • Public offering of shares of common stock (or pre-funded warrants) and accompanying Series A and Series B warrants

    Nov 21, 2024

    Announced: about US$42M · US$0.89 a share · Warrants at US$1.068 · Jefferies

    Dealers: Jefferies (lead)

    Announced Nov 20, 2024 · Announced Nov 21, 2024

Read by 6ix AI from the company's releases

Decks

Verrica Pharmaceuticals Inc. on 6ix

Sector
Health care
Industry
Pharmaceuticals
News releases
27 in the last 12 months · 142 in all · newest Nov 5, 2026 · oldest 2019
Calls
11 calls with a replay · 11 with a transcript · latest Aug 6, 2026
Decks
24 decks · latest September 2026

Where Verrica Pharmaceuticals Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:VRCA · Home listing · This pageNASDAQUnited StatesUSD
Lang & Schwarz:A41A98Lang & SchwarzGermanyEUR
Tradegate:1NE0TradegateGermanyEUR
BOATS:VRCABOATSUnited StatesUSD
gettex:1NE0gettexGermanyEUR
LS Exchange:A41A98LS ExchangeGermanyEUR
Frankfurt:1NE0FrankfurtGermanyEUR
Stuttgart:1NE0StuttgartGermanyEUR
Munich:1NE0MunichGermanyEUR

Log in to ask 6ix AI your own questions about Verrica Pharmaceuticals Inc.